Clinical Trial Search

Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: Adjudicated Incidence of Bleeding Events — 5.5; 12.7; 7.3; 18.3 percent of subjects with outcome event — p=.367

Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants

Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants

Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…

Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants

Primary: Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year — 3; 3 participants

Primary: Incidence of Atrial Fibrillation Requiring Treatment — 9; 21 participants — p=0.02

Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001

Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants

Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants

Primary: Usage of NOAC Based on Baseline Characteristics: Age at the Time of the First NOAC Initiation — 72.8; 72.5; 72.6; 74.0 Years

Primary: Incidence Rate (Per 1000 Participant-years) of Stroke in Non-valvular Atrial Fibrillation (AF) Participants Exposed to Oral Anticoagulation (OAC) and Unexposed to OAC…

Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants

Primary: Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period — 55; 56 Participants

Primary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients

Primary: The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist…

Primary: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF — 0; 2; 0; 0 Participants

Primary: Number of Patients With Clinically-Significant Bleeding — 14; 17 Participants

Primary: Number of Participants With Strokes — 0; 0 participants — p=1.0

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: Completion of Clinical Follow-up as a Measure of Feasibility — 20; 18 participants

Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95

Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants

Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days